Skip to main content
NCBI home page
Gut logoLink to Gut
. 1994 Mar;35(3):363–368. doi: 10.1136/gut.35.3.363

Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease.

G L Swift 1, E D Srivastava 1, R Stone 1, R D Pullan 1, R G Newcombe 1, J Rhodes 1, S Wilkinson 1, P Rhodes 1, G Roberts 1, B W Lawrie 1, et al.
PMCID: PMC1374591  PMID: 8150348

Abstract

One hundred and thirty patients with active symptoms of Crohn's disease were treated in a double blind randomised controlled trial with rifampicin, isoniazid, and ethambutol, or identical placebos for up to two years. All other treatment considered necessary was continued. Analyses were based on 126 patients, 63 in each treatment group. Thirty seven in the active and 30 in the placebo group had previous surgical procedures. There was no difference in concomitant treatment between the two groups. Thirty in the active and 46 in the placebo groups were taking corticosteroids at entry to the trial. Forty eight of 63 patients in the active and 49 of 63 in the placebo group, completed at least 12 months' therapy. Reasons for early withdrawal included pregnancy, adverse reaction, and failure to comply. There was no significant difference in the mean number of months completed between the two groups. Nineteen adverse reactions were recorded for 17 patients in the active group compared with three reactions in patients on placebo. All of the nine patients withdrawn early because of adverse reactions were in the active group. Fifteen patients on active treatment and 14 on placebo had surgery during the trial with no difference in the type of surgery required between the groups. Radiological assessments based on 98 patients at the end of the trial showed no significant differences between groups in changes of extent of disease. More patients developed strictures on placebo compared with active treatment but without a statistically significant difference. No differences were found between groups for the total prednisolone dose or the number of days on which prednisolone dose was 10 mg or above. Serial measurements of body weight and Crohn's disease activity index (CDAI) together with blood values for albumin, haemoglobin, white cell count, and platelets showed no consistent different differences between groups. There were occasional significant differences for some of these values between groups, which were not sustained. The trail provides little evidence of tangible benefit from the trail treatment.

Full text

PDF
363

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burnham W. R., Lennard-Jones J. E., Stanford J. L., Bird R. G. Mycobacteria as a possible cause of inflammatory bowel disease. Lancet. 1978 Sep 30;2(8092 Pt 1):693–696. doi: 10.1016/s0140-6736(78)92699-5. [DOI] [PubMed] [Google Scholar]
  2. Chiodini R. J., Van Kruiningen H. J., Merkal R. S., Thayer W. R., Jr, Coutu J. A. Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn's disease. J Clin Microbiol. 1984 Nov;20(5):966–971. doi: 10.1128/jcm.20.5.966-971.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chiodini R. J., Van Kruiningen H. J., Thayer W. R., Merkal R. S., Coutu J. A. Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig Dis Sci. 1984 Dec;29(12):1073–1079. doi: 10.1007/BF01317078. [DOI] [PubMed] [Google Scholar]
  4. Graham D. Y., Markesich D. C., Yoshimura H. H. Mycobacteria and inflammatory bowel disease. Results of culture. Gastroenterology. 1987 Feb;92(2):436–442. doi: 10.1016/0016-5085(87)90139-9. [DOI] [PubMed] [Google Scholar]
  5. Hampson S. J., Parker M. C., Saverymuttu S. H., Joseph A. E., McFadden J. J., Hermon-Taylor J. Quadruple antimycobacterial chemotherapy in Crohn's disease: results at 9 months of a pilot study in 20 patients. Aliment Pharmacol Ther. 1989 Aug;3(4):343–352. doi: 10.1111/j.1365-2036.1989.tb00221.x. [DOI] [PubMed] [Google Scholar]
  6. Harvey R. F., Bradshaw J. M. A simple index of Crohn's-disease activity. Lancet. 1980 Mar 8;1(8167):514–514. doi: 10.1016/s0140-6736(80)92767-1. [DOI] [PubMed] [Google Scholar]
  7. Järnerot G., Rolny P., Wickbom G., Alemayehu G. Antimycobacterial therapy ineffective in Crohn's disease after a year. Lancet. 1989 Jan 21;1(8630):164–165. doi: 10.1016/s0140-6736(89)91184-7. [DOI] [PubMed] [Google Scholar]
  8. Lennard-Jones J. E. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–19. doi: 10.3109/00365528909091339. [DOI] [PubMed] [Google Scholar]
  9. Mayberry J., Rhodes J., Matthews N., Wensinck F. Serum antibodies to anaerobic coccoid rods in patients with Crohn's disease or ulcerative colitis, and in medical and nursing staff. Br Med J (Clin Res Ed) 1981 Jan 10;282(6258):108–108. doi: 10.1136/bmj.282.6258.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. McFadden J. J., Butcher P. D., Chiodini R., Hermon-Taylor J. Crohn's disease-isolated mycobacteria are identical to Mycobacterium paratuberculosis, as determined by DNA probes that distinguish between mycobacterial species. J Clin Microbiol. 1987 May;25(5):796–801. doi: 10.1128/jcm.25.5.796-801.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Morgan K. L. Johne's and Crohn's. Chronic inflammatory bowel diseases of infectious aetiology? Lancet. 1987 May 2;1(8540):1017–1019. doi: 10.1016/s0140-6736(87)92280-x. [DOI] [PubMed] [Google Scholar]
  12. Picciotto A., Gesu G. P., Schito G. C., Testa R., Varagona G., Celle G. Antimycobacterial chemotherapy in two cases of inflammatory bowel disease. Lancet. 1988 Mar 5;1(8584):536–537. doi: 10.1016/s0140-6736(88)91334-7. [DOI] [PubMed] [Google Scholar]
  13. Sanderson J. D., Moss M. T., Tizard M. L., Hermon-Taylor J. Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Gut. 1992 Jul;33(7):890–896. doi: 10.1136/gut.33.7.890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Schultz M. G., Rieder H. L., Hersh T., Riepe S. Remission of Crohn's disease with antimycobacterial chemotherapy. Lancet. 1987 Dec 12;2(8572):1391–1392. doi: 10.1016/s0140-6736(87)91276-1. [DOI] [PubMed] [Google Scholar]
  15. Shaffer J. L., Hughes S., Linaker B. D., Baker R. D., Turnberg L. A. Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut. 1984 Feb;25(2):203–205. doi: 10.1136/gut.25.2.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Stanford J. L., White S. A., Burnham W. R., Lennard-Jones J. E., Bird R. G. Mycobacteria and inflammatory bowel disease. Lancet. 1979 Feb 24;1(8113):444–444. doi: 10.1016/s0140-6736(79)90922-x. [DOI] [PubMed] [Google Scholar]
  17. Tytgat G. N., Mulder C. J. The aetiology of Crohn's disease. Int J Colorectal Dis. 1986 Jul;1(3):188–192. doi: 10.1007/BF01648449. [DOI] [PubMed] [Google Scholar]
  18. Warren J. B., Rees H. C., Cox T. M. Remission of Crohn's disease with tuberculosis chemotherapy. N Engl J Med. 1986 Jan 16;314(3):182–182. doi: 10.1056/NEJM198601163140314. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES